Avoid diagnostic delays of alopecia areata (AA) in skin of color (SOC) patients, with NEW insights from Dr Yolanda Lenzy and patient Nikki Vontaya. Plus, get expert guidance on raising awareness of AA in SOC populations

Honored to be nominated for Vice-President elect of the AAD - I will 1. FIGHT FOR INFLATION-BASED MEDICARE REIMBURSEMENT 2. ADVOCATE FOR PRESERVING OF OUR SCOPE OF PRACTICE 3. ENSURE MISLEADING ADVERTISING IS COMBATTED 4. PROMOTE THE VALUE OF DERMATOLOGY

The ACR’s Musculoskeletal Ultrasound Certification in Rheumatology (RhMSUS) program is the only recognized certification for musculoskeletal ultrasound, & it’s valid for 10 years. Join a growing list of RhMSUS designees, earn a new credential, & improve your patient care by

Sensory neurons are both afferent and efferent and respond to many physical, inflammatory, and microbial stimuli. They also shape the scope and intensity of inflammation by acting on immune cells, stroma, epithelia, and even cancer.

I am excited to announce that dermatologist and dermatopathologist Dr. Elizabeth Newland will be joining the Department of Dermatology at Maryland University of Maryland School of Medicine & University of Maryland Medical Center! #dermtwitter

As more drugs are developed for AD — Which drug for which patient? 💊 🔬❓ Emma Guttman-Yassky discussed the Lancet article “Atopic Dematitis” with Dr. Christopher Bunick, at Practical Dermatology. See the video: bit.ly/EGuttmanADPrac… Icahn School of Medicine at Mount Sinai

Standing room only: Emma Guttman-Yassky presented “Atopic Dermatitis: An Evolving Success Story” at “Inflammatory Skin Diseases: The Translational Revolution” session, in which Dr. Guttman was the director. #AAD2025 #Orlando Icahn School of Medicine at Mount Sinai

If you look at what the American Academy of Dermatology Annual Meeting looks like today, and if I could show you what it looked like in 2015, you would not believe me. Imagine a world without abrocotinib, dupilumab, lebrikizumab, tralokinumab, ruxolitinib, upadacitinib, and

Had a great time at the 2025 American Academy of Dermatology Meeting. I discussed the evolving landscape and new developments in chronic pruritus of unknown origin, atopic dermatitis, chronic spontaneous urticaria, & prurigo nodularis #AAD2025 #dermtwitter

Hear from newly installed SOCS President Nada Elbuluk MD on the work of the #SkinofColorSociety and her vision for the future: hcplive.com/view/future-in… via @hcplive

🚨 News Alert 🚨 The FDA just released an important update regarding benzene in benzoyl peroxide products (fda.gov/drugs/drug-saf…). See below for my thoughts and products to avoid:

It was a pleasure to reunite with great friends and colleagues at #AAD2025! Last Friday, our reception for Alumni and Friends of Mount Sinai Dermatology was an astonishing success, bringing ~500 dermatologists, and pharma members that celebrated our achievements with us. Thanks to all who

such great news and warm congratulations!!!

This is one of the most brutally honest dialogues I have had about peer review. Peer review is valuable, but why? I am not sure we ask this question enough. It shouldn’t be a mindless, perfunctory, legacy enterprise. It should clearly and maybe even quantifiably bring value.

Today is a landmark moment in bioelectronic medicine and neuroimmunology. Prof. Kevin J. Tracey, MD and colleagues identified the inflammatory reflex over 25 years ago and now (today!) have delivered a FDA-approved device to treat autoimmunity. Viva la revolucion! businesswire.com/news/home/2025…

Lebrikizumab rapidly reduced IL-13–driven biomarkers and improved clinical outcomes in moderate-to-severe AD. This study by Emma Guttman-Yassky and colleagues confirms IL-13 as a central driver of systemic inflammation and a prime target for precision therapy 🔗 doi.org/10.1007/s13555…

If I told you I am making a tri-specific antibody that targets IL-1beta, IL-6, and TNF-alpha, every VC, investor, & pharma would run for the hills because of safety concerns. Yet, vagus nerve stimulation can lower all of these cytokines safely and improve rheumatoid arthritis.

Congrats to this trio of immunologists!

Phase I trial led by Dr. Nicholas Gulati tested topical diphencyprone for cutaneous neurofibromas in NF1. Safe and well tolerated, but only 1 of 12 patients showed partial response. A key step toward future therapies. 🔗 bit.ly/4nXkQhN Emma Guttman-Yassky

I triple down on this